OBJECTIVE: The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay. METHODS: HIV-1 coreceptor-usage was assessed using plasma samples from 406 HIV-1 infected patients by ESTA and by gp120 V3 population-sequencing followed by Geno2pheno (set at a False Positive Rate [FPR] of 10% and 5%). RESULTS: ESTA was successful in 365 (89.9%) samples indicating R5 in 254 (69.6%), and DM/X4 in 111 (30.4% of samples (104 [28.5%] DM and 7 [1.9%] X4). Genotypic-testing successfully assessed viral tropism for all 406 samples, including the 41 with undetermined result by ESTA. Genotypic-tropism testing at a FPR of 5% and 10% was 81.1% and 78.4% concordant with ESTA, respectively. Despite a sensitivity of 48.7% and 55.9% at a FPR of 5% and 10%, respectively, a high concordance (specificity: 95.3% for FPR of 5% and 88.2% for FPR of 10%) between genotypic-tropism testing and ESTA was reached in the detection of R5-tropic viruses. CONCLUSION: Our results are in line with other European studies, and support the routine use of genotypic tropism testing in clinical-settings for monitoring of HIV-1 infected patients candidate to or failing CCR5-antagonists.
OBJECTIVE: The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay. METHODS:HIV-1 coreceptor-usage was assessed using plasma samples from 406 HIV-1 infectedpatients by ESTA and by gp120 V3 population-sequencing followed by Geno2pheno (set at a False Positive Rate [FPR] of 10% and 5%). RESULTS: ESTA was successful in 365 (89.9%) samples indicating R5 in 254 (69.6%), and DM/X4 in 111 (30.4% of samples (104 [28.5%] DM and 7 [1.9%] X4). Genotypic-testing successfully assessed viral tropism for all 406 samples, including the 41 with undetermined result by ESTA. Genotypic-tropism testing at a FPR of 5% and 10% was 81.1% and 78.4% concordant with ESTA, respectively. Despite a sensitivity of 48.7% and 55.9% at a FPR of 5% and 10%, respectively, a high concordance (specificity: 95.3% for FPR of 5% and 88.2% for FPR of 10%) between genotypic-tropism testing and ESTA was reached in the detection of R5-tropic viruses. CONCLUSION: Our results are in line with other European studies, and support the routine use of genotypic tropism testing in clinical-settings for monitoring of HIV-1 infectedpatients candidate to or failing CCR5-antagonists.
Authors: Gabriela Bastos Cabral; João Leandro de Paula Ferreira; Luana Portes Osório Coelho; Mylva Fonsi; Denise Lotufo Estevam; Jaqueline Souza Cavalcanti; Luis Fernando de Macedo Brígido Journal: AIDS Res Hum Retroviruses Date: 2011-12-02 Impact factor: 2.205
Authors: Saleta Sierra; J Nikolai Dybowski; Alejandro Pironti; Dominik Heider; Lisa Güney; Alex Thielen; Stefan Reuter; Stefan Esser; Gerd Fätkenheuer; Thomas Lengauer; Daniel Hoffmann; Herbert Pfister; Björn Jensen; Rolf Kaiser Journal: PLoS One Date: 2015-05-13 Impact factor: 3.240
Authors: Sara Serafino; Eleonora Cella; Claudia Montagna; Eugenio Nelson Cavallari; Pietro Vittozzi; Alessandra Lo Presti; Marta Giovanetti; Laura Mazzuti; Ombretta Turriziani; Giancarlo Ceccarelli; Gabriella d'Ettorre; Vincenzo Vullo; Massimo Ciccozzi Journal: J Med Case Rep Date: 2015-11-03
Authors: Christian Pou; Francisco M Codoñer; Alexander Thielen; Rocío Bellido; Susana Pérez-Álvarez; Cecilia Cabrera; Judith Dalmau; Marta Curriu; Yolanda Lie; Marc Noguera-Julian; Jordi Puig; Javier Martínez-Picado; Julià Blanco; Eoin Coakley; Martin Däumer; Bonaventura Clotet; Roger Paredes Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240